Korro Bio Selects KRRO-111 for Clinical Development in AAT Deficiency
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2026
0mins
Source: NASDAQ.COM
- Clinical Candidate Selection: Korro Bio Inc. has selected KRRO-111 as a clinical development candidate for alpha-1 antitrypsin deficiency, marking a significant advancement in biopharmaceuticals and potentially offering new treatment options for approximately 3.4 million patients worldwide.
- Innovative Drug Mechanism: KRRO-111 is a proprietary GaINAc-conjugate oligonucleotide designed for subcutaneous delivery to liver cells, demonstrating over 90% success in RNA editing, which may effectively correct AAT transcription in liver cells, showcasing substantial therapeutic potential.
- Animal Model Validation: In mouse models, KRRO-111 has shown the production of circulating M-AAT protein, indicating its potential to improve lung and liver manifestations of the disease, further supporting its efficacy as a candidate for treating AATD.
- Data Presentation Plans: The company plans to present preclinical validation data for KRRO-111, emphasizing its potential in treating AATD, which may attract investor interest and drive stock price increases, currently trading at $9.32, up 1.86%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KRRO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KRRO
Wall Street analysts forecast KRRO stock price to rise
8 Analyst Rating
0 Buy
8 Hold
0 Sell
Hold
Current: 13.400
Low
7.00
Averages
25.75
High
81.00
Current: 13.400
Low
7.00
Averages
25.75
High
81.00
About KRRO
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Korro Bio Selects KRRO-111 for Clinical Development in AAT Deficiency
- Clinical Candidate Selection: Korro Bio Inc. has selected KRRO-111 as a clinical development candidate for alpha-1 antitrypsin deficiency, marking a significant advancement in biopharmaceuticals and potentially offering new treatment options for approximately 3.4 million patients worldwide.
- Innovative Drug Mechanism: KRRO-111 is a proprietary GaINAc-conjugate oligonucleotide designed for subcutaneous delivery to liver cells, demonstrating over 90% success in RNA editing, which may effectively correct AAT transcription in liver cells, showcasing substantial therapeutic potential.
- Animal Model Validation: In mouse models, KRRO-111 has shown the production of circulating M-AAT protein, indicating its potential to improve lung and liver manifestations of the disease, further supporting its efficacy as a candidate for treating AATD.
- Data Presentation Plans: The company plans to present preclinical validation data for KRRO-111, emphasizing its potential in treating AATD, which may attract investor interest and drive stock price increases, currently trading at $9.32, up 1.86%.
See More
Korro Bio Unveils KRRO-111 for AATD Treatment
- Therapeutic Innovation: Korro Bio's KRRO-111, a GalNAc-conjugated oligonucleotide, is designed for subcutaneous delivery to repair AAT mRNA, achieving over 90% SERPINA1 transcript editing and translating to approximately 90% functional alpha-1 antitrypsin (AAT) protein restoration in a mouse model, marking a significant advancement in AATD treatment.
- Preclinical Data: In mouse models, KRRO-111 nearly eliminated active Z protein production and reduced pre-existing aggregates by about 69% at day 28, indicating that the therapy could improve liver function while also addressing lung symptoms, highlighting its substantial clinical implications.
- Repeat Dose Potential: Preclinical studies suggest that KRRO-111 can achieve effects equivalent to DNA modification without altering the genome through a bi-weekly dosing regimen, showcasing the therapy's long-term application potential and offering a safer treatment option for patients.
- Market Outlook: Korro Bio plans to present additional data on KRRO-111 at future scientific meetings, and leveraging the advantages of its OPERA platform, the company is poised to lead in the AATD treatment space, addressing the urgent needs of approximately 3.4 million AATD patients worldwide.
See More
KORRO BIO INC Reports Quarterly EPS of $-1.69
- Financial Overview: The company reported a quarterly loss of $1.69 million.
- Market Impact: The financial results may influence investor confidence and stock performance.
- Future Projections: Analysts are closely monitoring upcoming strategies to improve profitability.
- Industry Context: The results reflect broader trends affecting the industry, including economic challenges.
See More
KORRO BIO INC - ANNOUNCES ZERO COLLABORATION REVENUE FOR Q1 2026
- Revenue Report Overview: The report details the revenue generated by KORROBIO for the first quarter of 2026.
- Collaboration Status: There is no collaboration reported in the current revenue figures, indicating a focus on independent operations.
See More
KORRO BIO INC ANTICIPATES CASH RESOURCES TO SUPPORT OPERATIONS THROUGH THE SECOND HALF OF 2028
- Funding Expectations: KORROBIO anticipates a cash position that will support its operations into the second half of 2028.
- Operational Strategy: The company is focusing on maintaining sufficient funds to ensure ongoing operational capabilities.
See More
Korro Bio Showcases RNA Editing Technology at Multiple International Conferences
- Conference Presentations: Korro Bio will present its GalNAc-conjugated oligonucleotide KRRO-121 at the 3rd International Conference on Ureagenesis Defects from April 22-24, 2026, showcasing its robust ammonia clearance in preclinical hyperammonemia models, highlighting its potential in treating rare diseases.
- ASGCT Participation: At the American Society of Gene and Cell Therapy Annual Meeting from May 11-15, 2026, Korro will discuss the effectiveness of its RNA editing oligonucleotide in restoring Alpha-1 Antitrypsin function in AATD models, demonstrating its application prospects in precision medicine.
- Technological Innovations: Korro's OPERA® platform will be featured at the TIDES USA conference from May 11-14, 2026, emphasizing its innovations in large-scale RNA editing that are crucial for generating drug candidates, potentially accelerating the development of new therapies.
- EASL Congress Involvement: At the EASL Congress from May 27-30, 2026, Korro will present research on the increased healthcare resource utilization associated with uncontrolled ammonia in hepatic encephalopathy, further underscoring its contributions to liver disease research.
See More
Korro Bio Selects KRRO-111 for Clinical Development in AAT Deficiency
- Clinical Candidate Selection: Korro Bio Inc. has selected KRRO-111 as a clinical development candidate for alpha-1 antitrypsin deficiency, marking a significant advancement in biopharmaceuticals and potentially offering new treatment options for approximately 3.4 million patients worldwide.
- Innovative Drug Mechanism: KRRO-111 is a proprietary GaINAc-conjugate oligonucleotide designed for subcutaneous delivery to liver cells, demonstrating over 90% success in RNA editing, which may effectively correct AAT transcription in liver cells, showcasing substantial therapeutic potential.
- Animal Model Validation: In mouse models, KRRO-111 has shown the production of circulating M-AAT protein, indicating its potential to improve lung and liver manifestations of the disease, further supporting its efficacy as a candidate for treating AATD.
- Data Presentation Plans: The company plans to present preclinical validation data for KRRO-111, emphasizing its potential in treating AATD, which may attract investor interest and drive stock price increases, currently trading at $9.32, up 1.86%.
See More
Korro Bio Unveils KRRO-111 for AATD Treatment
- Therapeutic Innovation: Korro Bio's KRRO-111, a GalNAc-conjugated oligonucleotide, is designed for subcutaneous delivery to repair AAT mRNA, achieving over 90% SERPINA1 transcript editing and translating to approximately 90% functional alpha-1 antitrypsin (AAT) protein restoration in a mouse model, marking a significant advancement in AATD treatment.
- Preclinical Data: In mouse models, KRRO-111 nearly eliminated active Z protein production and reduced pre-existing aggregates by about 69% at day 28, indicating that the therapy could improve liver function while also addressing lung symptoms, highlighting its substantial clinical implications.
- Repeat Dose Potential: Preclinical studies suggest that KRRO-111 can achieve effects equivalent to DNA modification without altering the genome through a bi-weekly dosing regimen, showcasing the therapy's long-term application potential and offering a safer treatment option for patients.
- Market Outlook: Korro Bio plans to present additional data on KRRO-111 at future scientific meetings, and leveraging the advantages of its OPERA platform, the company is poised to lead in the AATD treatment space, addressing the urgent needs of approximately 3.4 million AATD patients worldwide.
See More
KORRO BIO INC Reports Quarterly EPS of $-1.69
- Financial Overview: The company reported a quarterly loss of $1.69 million.
- Market Impact: The financial results may influence investor confidence and stock performance.
- Future Projections: Analysts are closely monitoring upcoming strategies to improve profitability.
- Industry Context: The results reflect broader trends affecting the industry, including economic challenges.
See More
KORRO BIO INC - ANNOUNCES ZERO COLLABORATION REVENUE FOR Q1 2026
- Revenue Report Overview: The report details the revenue generated by KORROBIO for the first quarter of 2026.
- Collaboration Status: There is no collaboration reported in the current revenue figures, indicating a focus on independent operations.
See More
KORRO BIO INC ANTICIPATES CASH RESOURCES TO SUPPORT OPERATIONS THROUGH THE SECOND HALF OF 2028
- Funding Expectations: KORROBIO anticipates a cash position that will support its operations into the second half of 2028.
- Operational Strategy: The company is focusing on maintaining sufficient funds to ensure ongoing operational capabilities.
See More
Korro Bio Showcases RNA Editing Technology at Multiple International Conferences
- Conference Presentations: Korro Bio will present its GalNAc-conjugated oligonucleotide KRRO-121 at the 3rd International Conference on Ureagenesis Defects from April 22-24, 2026, showcasing its robust ammonia clearance in preclinical hyperammonemia models, highlighting its potential in treating rare diseases.
- ASGCT Participation: At the American Society of Gene and Cell Therapy Annual Meeting from May 11-15, 2026, Korro will discuss the effectiveness of its RNA editing oligonucleotide in restoring Alpha-1 Antitrypsin function in AATD models, demonstrating its application prospects in precision medicine.
- Technological Innovations: Korro's OPERA® platform will be featured at the TIDES USA conference from May 11-14, 2026, emphasizing its innovations in large-scale RNA editing that are crucial for generating drug candidates, potentially accelerating the development of new therapies.
- EASL Congress Involvement: At the EASL Congress from May 27-30, 2026, Korro will present research on the increased healthcare resource utilization associated with uncontrolled ammonia in hepatic encephalopathy, further underscoring its contributions to liver disease research.
See More
